BUSINESS● LOW3h ago · Oct 22, 2026, 8:40 PM
Moderna falls 17.57% despite positive results for therapeutic cancer vaccine
Clarín · global
Moderna and Merck's experimental treatment significantly reduces the risk of relapse in melanoma patients. Moderna's shares fell after partial data leaked, reflecting market expectations rather than doubts about efficacy.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS22m agoVeriSign targets 6.5%-7% 2026 domain base growth as .web launch plans take shapeSeeking Alpha TechBUSINESS22m agoSS&C signals $6.736B-$6.776B 2026 revenue outlook while targeting 41% EBITDA margins exit rateSeeking Alpha Tech